This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
SAN FRANCISCO — The latest trials of combination hepatitis C drugs aimed at specific genotypes will get top billing at this year’s Liver Meeting.
“We have seen phenomenal change in hepatitis C treatment over the last 2 years, and this has not slowed down one bit,” said Gary Davis, MD, from MedLogician Consulting in Simpsonville, South Carolina, who is cochair of the American Association for the Study of Liver Diseases scientific program committee.
For the difficult-to-treat patients with genotype 3 and advanced fibrosis, a couple of the new drug combinations are providing “much improved” results, Dr Davis told Medscape Medical News.
The large phase 3 studies for hepatitis C treatments will be featured during late-breaker oral and poster sessions.
ASTRAL 1 looks at the combination of sofosbuvir and velpatasvir for the treatment of patients with hepatitis C genotype 1, 2, 4, 5, and 6, and ASTRAL 2 compares the fixed-dose combination of sofosbuvir and GS-5816 with the combination of sofosbuvir and ribavirin in patients with genotype 2.
ALLY-3+ evaluates the combination of daclatasvir, sofosbuvir, and ribavirin for patients with genotype 3, and TOPAZ-II looks at the combination of ombitasvir and paritaprevir plus dasabuvir, with or without ribavirin, in patients with genotype 1a.
And the C-EDGE Coinfection Study looks at the combination of grazoprevir and elbasvir in patients coinfected with hepatitis C and HIV.
Read more: http://www.medscape.com/viewarticle/854054